In this article, we are going to look at the 5 Best Medical Stocks to Buy Under $30. For a longer list and more details on how we picked these stocks, you can go to 10 Best Medical Stocks to Buy Under $30.
5. Avantor, Inc. (NYSE:AVTR)
Avantor, Inc. (NYSE:AVTR) is one of the best medical stocks to buy under $30. On April 1, William Blair reaffirmed its Market Perform rating on Avantor, Inc. (NYSE:AVTR) after the company announced the departure of its Chief Financial Officer, Brent Jones.
Jones will leave Avantor, Inc. (NYSE:AVTR) on or before June 24. Despite this leadership change, the company has maintained its 2026 guidance. This update comes after the company had cut its guidance twice in 2025 and an initial 2026 forecast that was below market expectations. William Blair pointed out that even with a volatile quarter, the company seems to be moving towards its full-year targets.
The CFO transition follows a recent change in the CEO position and the launch of Avantor, Inc.’s (NYSE:AVTR) Revival turnaround program. This program builds on earlier cost-cutting efforts that Jones had led.
William Blair also noted that the CFO departure was not a complete surprise, pointing out that roughly three-fourths of the companies in its coverage universe have experienced at least one CFO change in recent years.
Avantor, Inc. (NYSE:AVTR) is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. It serves as an important partner in research, development, and production in the medicine, healthcare, and technology markets.
4. Baxter International (NYSE:BAX)
Baxter International (NYSE:BAX) is one of the best medical stocks to buy under $30. On April 6, Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Baxter International (NYSE:BAX) from $23 to $22 while maintaining an Outperform rating on the stock. This comes as part of the firm’s first-quarter preview of the medical technology and life science tools sector.
Earlier, on March 30, Baxter International Inc. (NYSE:BAX) introduced the IV Verify Line Labeling System at the 2026 American Organization for Nursing Leadership Conference. This system is an automated solution that is designed to streamline nursing workflows, support safer medication administration at the bedside, and save clinician time. This launch by Baxter International Inc. (NYSE:BAX) comes after a strategic and exclusive distribution agreement with Vigilant Software, which specializes in medication management safe practices.
Clinicians will be able to use the IV Verify system to scan a medication barcode to instantly print a three-part adhesive label. The label will include the drug name, administration time, and tubing change times, which can then be placed on the tubing. This provides a clear and simple solution that supports labeling compliance and patient safety.
Baxter International (NYSE:BAX) is a medical technology company and an innovative leader in infusion therapies and platforms. It is known for its portfolio of connected solutions, medical devices, and advanced injectable technologies.
3. Roivant Sciences Ltd. (NASDAQ:ROIV)
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best medical stocks to buy under $30. On April 16, Piper Sandler assumed coverage of Roivant Sciences Ltd. (NASDAQ:ROIV) with an Overweight rating on the stock and $40 price target.
Piper Sandler said the stock has gained more than 190% over the past year, supported by positive data and execution across brepocitinib’s development in dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis. The research firm believes that brepocitinib has multi-blockbuster opportunities. It expects a possible dermatomyositis approval in the third quarter of 2026, Phase 3 CLARITY non-infectious uveitis (NIU) data in the second half of 2026, and the start of a Phase 3 study for cutaneous sarcoidosis by year-end 2026. Piper Sandler also pointed to expansion into lichen planopilaris.
Earlier, on March 20, Bernstein initiated coverage of Roivant Sciences Ltd. (NASDAQ:ROIV) with an Outperform rating and a price target of $35.
The research firm highlighted potential upside from upcoming readouts in Pulmonary Hypertension associated with Interstitial Lung Disease and Non-Infectious Uveitis. Despite this, Bernstein pointed to key risks, including negative results for brepocitinib if Vygart Phase 3 in Dermatomyositis seems better and a softer-than-expected launch for brepocitinib. The research firm noted that these risks are already appropriately discounted.
Roivant Sciences Ltd. (NASDAQ:ROIV) is an American biopharmaceutical company that focuses on improving drug development and commercialization through innovative technology. The company operates a unique model where it creates subsidiaries, known as “Vants,” to develop and commercialize a variety of medicines and technologies.
2. Viatris Inc. (NASDAQ:VTRS)
Viatris Inc. (NASDAQ:VTRS) is one of the best medical stocks to buy under $30. On March 23, Barclays increased its price target on Viatris Inc. (NASDAQ:VTRS) from $15 to $17 while keeping an Overweight rating on the stock.
Barclays noted that the muted market response to the company’s Investor Day was not surprising because of the economic environment. The research firm noted the lower expectations for EBITDA growth but highlighted Viatris Inc.’s (NASDAQ:VTRS) valuation.
According to Barclays, the stock is trading at around 6 times its earnings. The research firm believes that the market has not fully recognized the company’s potential for revenue growth and the value of its pipeline.
Barclays expects a rich fiscal year 2026 catalyst path to unfold for the pharmaceutical company. The firm sees ample upside in the near term as these catalysts play out.
Looking ahead, Barclays expects to see several important developments and catalysts for Viatris Inc. (NASDAQ:VTRS) in fiscal year 2026. The firm believes there is potential for the stock to rise in the near term as these catalysts play out.
Viatris Inc. (NASDAQ:VTRS) is a global healthcare company focused on providing access to generic and brand-name medicines across various therapeutic areas.
1. Pfizer Inc. (NYSE:PFE)
Pfizer Inc. (NYSE:PFE) is one of the best medical stocks to buy under $30. On April 20, Pfizer Inc. (NYSE:PFE) announced, together with Astellas Pharma Inc., that the US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) for Priority Review.
The application is for the use of PADCEV (enfortumab vedotin-ejfv) in combination with the PD-1 inhibitor Keytruda (pembrolizumab), or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph), as a perioperative treatment, given before and after surgery, for patients with muscle-invasive bladder cancer (MIBC).
This regimen was already approved by the FDA in November 2025 for patients with MIBC who are not eligible for cisplatin. The new application aims to expand the indication to patients with MIBC, regardless of whether they are eligible for cisplatin or not.
According to the report by Pfizer Inc. (NYSE:PFE), the FDA grants Priority Review to medicines that may offer major improvements in treatment or address conditions where there are limited therapy options. Under the Prescription Drug User Fee Act (PDUFA), a target action date of August 17, 2026, has been set by the FDA.
Pfizer Inc. (NYSE:PFE) is a leading pharmaceutical company that focuses on the discovery, development, and manufacture of healthcare products, medicines, and vaccines.
While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best Fintech Stocks to Invest In According to Billionaires and 10 Unrivaled Stocks of the Next 5 Years.
Disclosure: None.
